

HR 6757

Insulin Savings for Patients Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 18, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Feb 21, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/6757>

Sponsor

Name: Rep. Burgess, Michael C. [R-TX-26]

Party: Republican • **State:** TX • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Miller-Meeks, Mariannette [R-IA-2]	R · IA		Feb 18, 2022
Rep. McKinley, David B. [R-WV-1]	R · WV		Mar 30, 2022
Rep. Van Drew, Jefferson [R-NJ-2]	R · NJ		Mar 31, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 21, 2022
Ways and Means Committee	House	Referred To	Feb 18, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Feb 18, 2022)

Insulin Savings for Patients Act

This bill requires 100% of negotiated price concessions for covered insulin products under the Medicare prescription drug benefit to be reflected at the point of sale by 2024. The Government Accountability Office must annually report on the effects of the bill's implementation, including with respect to insulin prices.

Actions Timeline

- **Feb 21, 2022:** Referred to the Subcommittee on Health.
- **Feb 18, 2022:** Introduced in House
- **Feb 18, 2022:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.